Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants

Armin Spök, Richard M. Twyman, Rainer Fischer, Julian K.C. Ma, Penelope A.C. Sparrow

    Research output: Contribution to journalReview articleResearchpeer-review

    Abstract

    The use of genetically modified (GM) plants to synthesize proteins that are subsequently processed, regulated and sold as pharmaceuticals challenges two very different established regulatory frameworks, one concerning GM plants and the other covering the development of biotechnology-derived drugs. Within these regulatory systems, specific regulations and guidelines for plant-made pharmaceuticals (PMPs) - also referred to as plant-derived pharmaceuticals (PDPs) - are still evolving. The products nearing commercial viability will ultimately help to road test and fine-tune these regulations, and might help to reduce regulatory uncertainties. In this review, we summarize the current state of regulations in different countries, discuss recent changes and highlight the need for further regulatory development in this burgeoning, new industry. We also make the case for the harmonization of international regulations.

    Original languageEnglish
    Pages (from-to)506-517
    Number of pages12
    JournalTrends in biotechnology
    Volume26
    Issue number9
    DOIs
    Publication statusPublished - 1 Sep 2008

    Fingerprint

    Genetically modified plants
    Genetically Modified Plants
    Drug products
    Medicinal Plants
    Pharmaceutical Preparations
    Biotechnology
    Uncertainty
    Proteins
    Industry
    Guidelines

    ASJC Scopus subject areas

    • Biotechnology
    • Bioengineering

    Cite this

    Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants. / Spök, Armin; Twyman, Richard M.; Fischer, Rainer; Ma, Julian K.C.; Sparrow, Penelope A.C.

    In: Trends in biotechnology, Vol. 26, No. 9, 01.09.2008, p. 506-517.

    Research output: Contribution to journalReview articleResearchpeer-review

    Spök, Armin ; Twyman, Richard M. ; Fischer, Rainer ; Ma, Julian K.C. ; Sparrow, Penelope A.C. / Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants. In: Trends in biotechnology. 2008 ; Vol. 26, No. 9. pp. 506-517.
    @article{12f3f77b42cd43cf8ee7a8b1f54b17d0,
    title = "Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants",
    abstract = "The use of genetically modified (GM) plants to synthesize proteins that are subsequently processed, regulated and sold as pharmaceuticals challenges two very different established regulatory frameworks, one concerning GM plants and the other covering the development of biotechnology-derived drugs. Within these regulatory systems, specific regulations and guidelines for plant-made pharmaceuticals (PMPs) - also referred to as plant-derived pharmaceuticals (PDPs) - are still evolving. The products nearing commercial viability will ultimately help to road test and fine-tune these regulations, and might help to reduce regulatory uncertainties. In this review, we summarize the current state of regulations in different countries, discuss recent changes and highlight the need for further regulatory development in this burgeoning, new industry. We also make the case for the harmonization of international regulations.",
    author = "Armin Sp{\"o}k and Twyman, {Richard M.} and Rainer Fischer and Ma, {Julian K.C.} and Sparrow, {Penelope A.C.}",
    year = "2008",
    month = "9",
    day = "1",
    doi = "10.1016/j.tibtech.2008.05.007",
    language = "English",
    volume = "26",
    pages = "506--517",
    journal = "Trends in biotechnology",
    issn = "0167-7799",
    publisher = "Elsevier Limited",
    number = "9",

    }

    TY - JOUR

    T1 - Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants

    AU - Spök, Armin

    AU - Twyman, Richard M.

    AU - Fischer, Rainer

    AU - Ma, Julian K.C.

    AU - Sparrow, Penelope A.C.

    PY - 2008/9/1

    Y1 - 2008/9/1

    N2 - The use of genetically modified (GM) plants to synthesize proteins that are subsequently processed, regulated and sold as pharmaceuticals challenges two very different established regulatory frameworks, one concerning GM plants and the other covering the development of biotechnology-derived drugs. Within these regulatory systems, specific regulations and guidelines for plant-made pharmaceuticals (PMPs) - also referred to as plant-derived pharmaceuticals (PDPs) - are still evolving. The products nearing commercial viability will ultimately help to road test and fine-tune these regulations, and might help to reduce regulatory uncertainties. In this review, we summarize the current state of regulations in different countries, discuss recent changes and highlight the need for further regulatory development in this burgeoning, new industry. We also make the case for the harmonization of international regulations.

    AB - The use of genetically modified (GM) plants to synthesize proteins that are subsequently processed, regulated and sold as pharmaceuticals challenges two very different established regulatory frameworks, one concerning GM plants and the other covering the development of biotechnology-derived drugs. Within these regulatory systems, specific regulations and guidelines for plant-made pharmaceuticals (PMPs) - also referred to as plant-derived pharmaceuticals (PDPs) - are still evolving. The products nearing commercial viability will ultimately help to road test and fine-tune these regulations, and might help to reduce regulatory uncertainties. In this review, we summarize the current state of regulations in different countries, discuss recent changes and highlight the need for further regulatory development in this burgeoning, new industry. We also make the case for the harmonization of international regulations.

    UR - http://www.scopus.com/inward/record.url?scp=48849103075&partnerID=8YFLogxK

    U2 - 10.1016/j.tibtech.2008.05.007

    DO - 10.1016/j.tibtech.2008.05.007

    M3 - Review article

    VL - 26

    SP - 506

    EP - 517

    JO - Trends in biotechnology

    JF - Trends in biotechnology

    SN - 0167-7799

    IS - 9

    ER -